Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

Breast Cancer Research and Treatment

Volumn 147, Issue 3, 2014, Pages 557-570

  Vulsteke, C ^a   Pfeil, A M ^b   Schwenkglenks, M ^b   Pettengell, R ^c   Szucs, T D ^b   Lambrechts, D ^d,e   Peeters, M ^f   van Dam, P ^f   Dieudonne A S ^g   Hatse, S ^g,h   Neven, P ^g,h   Paridaens, R ^g,h   Wildiers, H ^g,h  

^a Integrated Cancer Center Ghent AZ Maria Middelares   (Belgium)

^b UNIVERSITY OF BASEL   (Switzerland)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer specific survival; Chemotherapy; Early breast cancer; Germline genetic variability; Recurrence free interval; Single nucleotide polymorphisms

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C9; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYP2C9 PROTEIN, HUMAN; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; TAXOID; UGT2B7 PROTEIN, HUMAN;

ABCB1 GENE; ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CYP2C9 GENE; DISEASE ASSOCIATION; DRUG METABOLISM; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADJUVANT THERAPY; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2C9; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; NEOADJUVANT THERAPY; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS; TREATMENT OUTCOME;

EID: 84918515552     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3105-5     Document Type: Article

References (49)

1. Roché H, Fumleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients. The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664–5671
2. Ganz PA, Kwan L, Stanton AL et al (2011) Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 9:1101–1109
3. Hasset MJ, O’Malley AJ, Pakes JR et al (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108–1117
4. Vulsteke C, Lambrechts D, Dieudonné AS et al (2013) Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24(6):1513–1525
5. Pfeil AM, Vulsteke C, Paridaens R et al (2014) Multivariable regression analysis of febrile neutropenia occurence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic riks factors. BMC Cancer 14:201
6. Pastina L, Giovannetti E, Chioni A et al (2010) Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in castration-resistant prostate cancer (CRPC) patients. BMC Cancer 27(10):511
7. Reumers J, De Rijk P, Zhao H et al (2011) Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol 30:61–68
8. Goldhirsch A, Winer E, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223
9. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481
10. Wellek S (1993) A log-rank test for equivalence of two survivor functions. Biometrics 49:877–881
11. Cox DR (1972) Regression Models and Life-Tables. J R Stat Soc Ser B Methodol. 34(2):187–220
12. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69(1):239–241
13. Cox DR, Snell EJ (1968) A general definition of residuals. J R Stat Soc Ser B Methodol 30(2):248–275
14. Bosch TM, Meijerman I, Beijnen JH et al (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285
15. Gor PP, Su HI, Gray RJ et al (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer, a retrospective cohort study. Breast Cancer Res 12(3):R26
16. Bray J, Sludden J, Griffin MJ et al (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicine and cyclophosphamide. Br J Cancer 102(6):1003–1009
17. Semsei AF, Erdelyi DJ, Ungvari I et al (2012) ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia. Cell Biol Int 36(1):79–86
18. Visscher H, Ross CJ, Rassekh SR et al (2012) Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30(13):1422–1428
19. Wojnowski L, Kulle B, Schirmer M et al (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 13;112(24):3754–3762
20. Guzik TJ, West NE, Black E et al (2000) Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102:1744–1747
21. Wyche KE, Wang SS, Griendling KK et al (2004) C242T CYBA polymorphism of the NADPH oxidase is associated with reduced respiratory burst in human neutrophils. Hypertension 43:1246–1251
22. Shimo-Nakanishi Y, Hasebe T, Suzuki A et al (2004) Functional effects of NAD(P)H oxidase p22(phox)C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 175:109–115
23. Schirmer M, Hoffmann M, Kaya E et al (2008) Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenomics J 4:297–304
24. Hoffman M, Schirmer M, Tzvetkov M et al (2010) A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res 70(6):2328–2338
25. Rossi D, Rasi S, Franceschetti S et al (2009) Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large cell lymphoma treated with R-CHOP21. Leukemia 6:1118–1126
26. Parmar S, Stingl JC, Huber-Wechselberger A et al (2011) Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Res 13(3):R57
27. Kafka A, Sauer G, Jaeger C et al (2003) Polymorphism C3435T of the MDR-1 predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117–1121
28. Sohn KJ, Croxford R, Yates Z et al (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134–144
29. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al (2010) Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69(1):58–66
30. Nakajima M, Komagata S, Fujiki Y et al (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in japanese cancer patients. Pharmacogenet Genom 17(6):431–445
31. Udler M, Maia AT, Cebrian A et al (2007) Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25(21):3015–3023
32. Sweeney C, Ambrosone CB, Joseph L et al (2003) Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103(6):810–814
33. Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24(23):3747–3755
34. Fagerholm R, Hofstetter B, Tommiska J et al (2008) NAD(P)H: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40(7):844–853
35. Bewick MA, Conlon MS, Lafrenie RM et al (2008) Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 111:93–101
36. Sun Z, Chen J, Aakre J et al (2010) Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 21(10):2011–2016
37. Jaremko M, Justenhoven C, Schroth W et al (2007) Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 17(7):529–538
38. Lai JI, Tzeng CH, Chen PM et al (2009) Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 100(7):1261–1266
39. Khrunin AV, Moisseev A, Gorbunova V et al (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10(1):54–61
40. Paik KY, Lee IK, Lee YS et al (2014) Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients. Cancer Res Treat 46(1):65–73
41. Pei D, Zhu F, Chen X et al (2014) Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection. Biomed Pharmacother. Epub ahead of print
42. Iwase R, Shiba H, Haruki K et al (2013) Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma. Anticancer Res 33(8):3439–3444
43. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
44. Lu H, Ouyang W, Huang C et al (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4:221–233
45. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444
46. Lee IK, Vansaun MN, Shim JH et al (2013) Increased metastases are associated with inflammation and matrix metalloproteinase-9 activity at incision sites in a murine model of peritoneal dissemination of colorectal cancer. J Surg Res 180:252–259
47. Dignam JJ, Dukic V, Anderson SJ et al (2009) Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 116:595–602
48. Brouckaert O, Laenen A, Vanderhaegen J et al (2012) Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 23(10):2578–2584
49. Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 21(17):3244–3248